Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Glucagon Like Peptide 2 Receptor (GLP2R) - Overview Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Glucagon Like Peptide 2 Receptor (GLP2R) - Companies Involved in Therapeutics Development Adocia SAS Hanmi Pharmaceuticals Co Ltd Naia Ltd PhaseBio Pharmaceuticals Inc Sosei Heptares Takeda Pharmaceutical Co Ltd Tasly Pharmaceutical Group Co Ltd Therachon AG Zealand Pharma AS Glucagon Like Peptide 2 Receptor (GLP2R) - Drug Profiles apraglutide - Drug Profile Product Description Mechanism Of Action R&D Progress elsiglutide - Drug Profile Product Description Mechanism Of Action R&D Progress Fusion Protein to Agonize GLP2R for Short Bowel Syndrome - Drug Profile Product Description Mechanism Of Action R&D Progress glepaglutide - Drug Profile Product Description Mechanism Of Action R&D Progress GXG-8 - Drug Profile Product Description Mechanism Of Action R&D Progress HM-15912 - Drug Profile Product Description Mechanism Of Action R&D Progress NB-1002 - Drug Profile Product Description Mechanism Of Action R&D Progress Peptide to Agonize GLP2R for Intestinal Diseases - Drug Profile Product Description Mechanism Of Action R&D Progress teduglutide - Drug Profile Product Description Mechanism Of Action R&D Progress teduglutide - Drug Profile Product Description Mechanism Of Action R&D Progress ZP-7570 - Drug Profile Product Description Mechanism Of Action R&D Progress ZPGG-72 - Drug Profile Product Description Mechanism Of Action R&D Progress Glucagon Like Peptide 2 Receptor (GLP2R) - Dormant Products Glucagon Like Peptide 2 Receptor (GLP2R) - Product Development Milestones Featured News & Press Releases Mar 25, 2019: Therachon presents data from preclinical and phase I clinical studies of Apraglutide for the treatment of Short Bowel Syndrome at ASPEN 2019 Nutrition Science & Practice Conference Feb 05, 2019: Pharm-Olam enrolls patients in Zealand Pharma orphan drug study Jan 16, 2019: Therachon is granted Orphan Drug Designation by US FDA for Apraglutide for the treatment of Short Bowel Syndrome Nov 29, 2018: Therachon is granted Orphan Drug Designation in the European Union for apraglutide for the treatment of short bowel syndrome Nov 13, 2018: U.S. FDA accepts for filing Shire's supplemental New Drug Application for GATTEX (teduglutide [rDNA origin]) for children with Short Bowel Syndrome Oct 05, 2018: Zealand Pharma enrols first patient in Phase lll study of glepaglutide May 31, 2018: Zealand Pharma to present new clinical Phase 2 results on glepaglutide for the treatment of short bowel syndrome at the DDW conference in the U.S. Apr 26, 2018: Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome Apr 09, 2018: Revestive is accepted for restricted use within NHS Scotland Jan 23, 2018: New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome Jan 23, 2018: Zealand Pharma to present Phase 2 results on glepaglutide at the ASPEN 2018 Conference in Las Vegas, U.S. Jan 22, 2018: Shire to Present Data on Short Bowel Syndrome With Intestinal Failure at the ASPEN 2018 Nutrition Science & Practice Conference Nov 14, 2017: Recruitment completed in trial to evaluate the optimal dosing frequency for Zealands long-acting GLP-2 analog glepaglutide Oct 24, 2017: U.S. FDA Grants Orphan Drug Designation to Glepaglutide for the Treatment of Short Bowel Syndrome Oct 12, 2017: Zealand has initiated a clinical trial to evaluate the potential for less than once-daily dosing with its long-acting GLP-2 analog glepaglutide Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2019 Number of Products under Development by Therapy Areas, H1 2019 Number of Products under Development by Indication, H1 2019 Number of Products under Development by Companies, H1 2019 Products under Development by Companies, H1 2019 Products under Development by Companies, H1 2019 (Contd..1), H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Stage and Route of Administration, H1 2019 Number of Products by Stage and Molecule Type, H1 2019 Pipeline by Adocia SAS, H1 2019 Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2019 Pipeline by Naia Ltd, H1 2019 Pipeline by PhaseBio Pharmaceuticals Inc, H1 2019 Pipeline by Sosei Heptares, H1 2019 Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019 Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2019 Pipeline by Therachon AG, H1 2019 Pipeline by Zealand Pharma AS, H1 2019 Dormant Projects, H1 2019List of Figures Number of Products under Development by Stage of Development, H1 2019 Number of Products under Development by Therapy Areas, H1 2019 Number of Products under Development by Top 10 Indications, H1 2019 Number of Products by Mechanism of Actions, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Top 10 Routes of Administration, H1 2019 Number of Products by Stage and Top 10 Routes of Administration, H1 2019 Number of Products by Top 10 Molecule Types, H1 2019 Number of Products by Stage and Top 10 Molecule Types, H1 2019

Adocia SAS Hanmi Pharmaceuticals Co Ltd Naia Ltd PhaseBio Pharmaceuticals Inc Sosei Heptares Takeda Pharmaceutical Co Ltd Tasly Pharmaceutical Group Co Ltd Therachon AG Zealand Pharma AS